Vol.

No.

May 03, 2024May 03, 2024

DOWNLOAD THE PDF

Over three years as CEO, Karen Knudsen led ACS through COVID—and reversed the charity’s long slump

Cover Story

Conversation with The Cancer Letter Free

Over three years as CEO, Karen Knudsen led ACS through COVID—and reversed the charity’s long slump

Over the past three years, the American Cancer Society has recovered from the fundraising decline brought on by COVID-19 and has reversed the years-long fundraising slump in public support.

Health Equity White House

Citing need for “more conversations” on menthol, White House scuttles move to ban the flavor favored by Black smokers

By McKenzie Prillaman

Conversation with The Cancer Letter

USPSTF’s Wanda Nicholson: Final recommendation to start breast cancer screening at 40 will save 20% more lives

By Matthew Bin Han Ong

Clinical Trials & Tribulations

Canine cancers as models: We have barely tapped the full potential of comparative oncology

By Christina K. Lopes

Free In the Archives

Otis Brawley discusses health disparities, UChicago pioneering oncologists on the UChicago Cancer Luminaries Podcast

In Brief

Cold Spring Harbor and Northwell extend collaboration with $150M commitment

Miriam Merad named dean for Translational Research and Therapeutic Innovation at Mt. Sinai

Sana Karam to lead radiation oncology at Siteman

MD Anderson and PAHO collaborate to support cancer prevention, control in Americas

Funding Opportunities

DOD Rare Cancers Research Program funding opportunities for FY24

Clinical Roundup

Lower MRD prior to HCT associated with better outcomes in FLT3-ITD AML

Cancer screening rates are significantly lower in FQHCs

Keytruda combination improves OS for HER2-positive advanced gastric cancer in phase III trial

Enhertu improves PFS in HR-positive, HER2-low breast cancer in phase III trial

Glecirasib shows positive ORR for KRASG12C mutated-NSCLC in phase II trial

Breast cancer screening tool predicts patient response to immunotherapies

One-tube test could expand cervical cancer screening, speed diagnosis

APC activation, CDK inactivation triggers “doubling” in cancer cell division

Drugs & Targets

FDA rule focuses on the safety and effectiveness of LDTs

FDA issues additional draft guidance on eligibility criteria for cancer drug clinical trials

CHMP recommends approval of fruquintinib for previously-treated mCRC

NCI Trials

NCI Trials for May 2024

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE